Clinical Trial Details

NCT ID: NCT03195140
Date Last Changed: July 24, 2017

Overview

Research Study Summary

A clinical study for patients with Diabetes Mellitus, Type 1

Research Study Title

Tandem PLGS Pivotal Trial: A Randomized Clinical Trial to Assess the Efficacy of Predictive Low Glucose Suspend Versus Sensor-augmented Pump Therapy in the Management of Type 1 Diabetes

Purpose

A 6-week crossover study will compare PLGS to SAP outcomes in adults and youth > 6 years old with type 1 diabetes (T1D).

To Learn more

Recruitment Details

Gender
All
Age
6 and up
Overall Status
Recruiting
Lead Sponsor
Tandem Diabetes Care, Inc.
Duration
4 Months
Facility Type
N/A
Compensation

Eligibility

All ages 6 Years and up

Inclusion Criteria:

    1. Clinical diagnosis, based on investigator assessment, of T1D treated with insulin via an insulin pump or injections for at least 1 year, with no major change in the intensity of insulin therapy in the past 3 months (e.g. switching from injections to pump)
    1. Age ≥6.0 years old
    1. For participants < 18 years old, living with one or more parents or guardians committed to participating in training and able to contact the participant in case of an emergency
    1. For females, not currently known to be pregnant
    • If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females of child-bearing potential. Subjects who become pregnant will be discontinued from the study. Also, subjects who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.
    1. Investigator has confidence that the participant can successfully use all study devices and is capable of adhering to the protocol

Exclusion Criteria:

    1. Anticipated need to use acetaminophen during study participation
    1. Participation in another pharmaceutical or device trial at the time of enrollment or plan to participate in another study during the time period of participation in this study
    1. Employed by, or having immediate family members employed by Tandem; or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial
    1. A condition, which in the opinion of the investigator or designee, would put the participant or study at risk including any contraindication to the use of any of the study devices per FDA labelling
    • Individuals should not be enrolled with uncontrolled thyroid disease, renal failure (e.g., dialysis or estimated glomerular filtration (eGFR) < 30), hemophilia or another major bleeding disorder, or unstable cardiovascular disease.
    • Laboratory testing and other work up needed to determine that an individual is a suitable candidate for the study should be performed as part of usual care.

Site Locations (2)

Country State City Zip Facility and Contact
United States California Santa Barbara 93105 William Sansum Diabetes Center
Laura Lindsey
805-682-7640 ext. 221
lliindesy@sansum.org

Jordan Pinsker
Principal Investigator
United States Colorado Aurora 80045 Barbara Davis Center
Emily Jost
303-724-7313
emily.jost@ucdenver.edu

Gregory Forlenza
Principal Investigator

Contact

Trevor J Denbo, MS
858-224-6136
E-mail:

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.